Clinical and biochemical features of the course of COVID-19 in patients with arterial hypertension

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

Purpose. To study the clinical and biochemical features of the course of coronavirus infection (COVID-19) in patients with arterial hypertension (AH).

Material and methods. The retrospective study included 74 patients with COVID-19 treated in hospital (37 men and 37 women; median age: 55.0 [45.0, 59.0] years). The patients were divided into 2 groups: 1st (n=48) – patients with hypertension who had COVID-19; 2nd (n=26) – patients without concomitant cardiovascular pathology who had COVID-19. Patients were assessed daily (for 7 days) for the clinical symptoms of the disease with an assessment of complaints, respiratory rate, heart rate, SpO2. A study of the level of C-reactive protein (CRP), D-dimer, and ferritin was carried out initially, on the 3-5th and 8-10th days in the hospital.

Results. In group 1, compared with group 2, cough, shortness of breath, myalgia (with minimization of symptoms during treatment), as well as significantly higher values of CRP and D-dimer were statistically significantly more common. At the same time, cough, shortness of breath and myalgia in patients with COVID-19 and hypertension were more pronounced at the onset of the disease, in contrast to patients without hypertension. An increase in CRP and D-dimer indicators determines the severity of the condition of patients with comorbid pathology at the onset of the disease and requires timely hospitalization of this category of patients.

Sobre autores

A. Mordyk

Omsk State Medical University, Ministry of Health of Russia; National Medical Research Center for Phthisiopulmonology and Infectious Diseases, Ministry of Health of Russia

Autor responsável pela correspondência
Email: ppi100@mail.ru
ORCID ID: 0000-0001-6196-7256

Professor, MD

Rússia, Omsk; Moscow

N. Bagisheva

Omsk State Medical University, Ministry of Health of Russia

Email: ppi100@mail.ru
ORCID ID: 0000-0003-3668-1023

Candidate of Medical Sciences

Rússia, Omsk

M. Moiseeva

Omsk State Medical University, Ministry of Health of Russia

Email: ppi100@mail.ru
ORCID ID: 0000-0003-3458-9346

Candidate of Medical Sciences

Rússia, Omsk

E. Antipova

Omsk State Medical University, Ministry of Health of Russia

Email: ppi100@mail.ru
Rússia, Omsk

V. Streltsova

Omsk State Medical University, Ministry of Health of Russia

Email: ppi100@mail.ru
Rússia, Omsk

Bibliografia

  1. Антипова Е.П., Моисеева М.В., Багишева Н.В. и др. COVID-19 в когорте пациентов с артериальной гипертензией: роль рецепторов ангиотензинпревращающего фермента. Забайкальский медицинский вестник. 2023; 1: 104–12 [Antipova E.P., Moiseeva M.V., Bagisheva N.V. et al Arterial hypertension and COVID-19: the role of angiotensin-converting enzyme receptors in infection. Transbaikal Medical Bulletin. 2023; 1: 104–12 (in Russ.)]. doi: 10.52485/19986173_2023_1_104
  2. Моисеева М.В., Багишева Н.В., Мордык А.В. и др. Что известно о влиянии артериальной гипертензии на течение COVID-19. Клинический разбор в общей медицине. 2022; 5: 6–9 [Moiseeva M.V., Bagisheva N.V., Mordyk A.V., et al. What is known about the impact of hypertension on the course of COVID-19. Clinical Review for General Practice. 2022; 5: 6–9 (in Russ.)]. doi: 10.47407/kr2022.3.5.00156
  3. Насонов Е.Л. Иммунопатология и иммунофармакотерапия коронавирусной болезни 2019. (COVID-19): фокус на интерлейкин-6. Научно-практическая ревматология. 2020; 58 (3): 245–61 [Nasonov E.L. Immunopathology and immunopharmacotherapy of coronavirus disease 2019 (COVID-19): focus on interleukin-6. Rheumatology Science and Practice. 2020; 58 (3): 245–61 (in Russ.).]. doi: 10.14412/1995-4484-2020-245-261
  4. Подзолков В.И., Брагина А.Е., Тарзиманова А.И. и др. Артериальная гипертензия и неблагоприятное течение COVID-19 среди госпитализированных больных: данные когортного исследования из России. Рациональная Фармакотерапия в Кардиологии. 2023; 19 (1): 4–10 [Podzolkov V.I., Bragina A.E., Tarzimanova A.I. et al. Arterial Hypertension and Severe COVID-19 in Hospitalized Patients: Data from a Cohort Study. Rational Pharmacotherapy in Cardiology. 2023; 19 (1): 4–10 (in Russ.)]. doi: 10.20996/1819-6446-2023-01-10
  5. Хабибулина М.М., Шамилов М.Д. Пандемия COVID-19: эмоциональное выгорание у медицинских сестер 3 года спустя. Медицинская сестра. 2024; 26 (2): 51–8 [Khabibulina M.M., Shamilov M.D. COVID-19 pandemic: Emotional burnout in nurses (3 years later). Meditsinskaya sestra. 2024; 26 (2): 51–8 (in Russ.)]. doi: 10.29296/25879979-2024-02-11
  6. Aziz M., Fatima R., Assaly R. Elevated interleukin-6 and severe COVID-19: A meta- analysis. J Med Virol. 2020; 92 (11): 2283. doi: 10.1002/jmv.25948
  7. Cao Y., Liu X, Xiong L., Cai K. Imaging and clinical features of patients with 2019 novel c oronavirus SARS-CoV-2: a systematic review and meta-analysis. J Med Virol. 2020; 92 (9): 1449–59. doi: 10.1002/jmv.25822
  8. Diao B., Wang C., Tan Y. et al. Reduction and functional exhaustion of T Cells in patients with coronavirus disease 2019 (COVID-19). MedRxiv. 2020: 827. doi: 10.1101/2020.02.18.20024364
  9. Mehta P., McAuley D.F., Brown M. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395 (10229): 1033–4. doi: 10.1016/S0140-6736(20)30628-0
  10. Ruan Q., Yang K., Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020; 46 (5): 846–8. doi: 10.1007/s00134-020-05991
  11. Sun X., Wang T., Cai D. et al. Сytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020; 53: 38–42. doi: 10.1016/j.cytogfr.2020.04.002
  12. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020; 50 (4): 332–4. doi: 10.1016/j.medmal.2020.03.007
  13. Wu C., Chen X., Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180 (7): 934–43. doi: 10.1001/jamainternmed.2020.0994
  14. Yun H., Sun Z., Wu J. et al. Laboratory data analysis of novel coronavirus (COVID-19) screening in 2510 patients. Clin Chim Acta. 2020; 507: 94–7. doi: 10.1016/j.cca.2020.04.018
  15. Zhu Z., Cai T., Fan L. et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis. 2020; 96: 332–9. doi: 10.1016/j.ijid.2020.04.041
  16. Zhu J., Ji P., Pang J. et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J Med Virol. 2020; 92 (10): 1902–14. doi: 10.1002/jmv.25884

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies